Tumor-associated macrophages and anti-tumor therapies: complex links
- PMID: 26956893
- PMCID: PMC11108407
- DOI: 10.1007/s00018-016-2166-5
Tumor-associated macrophages and anti-tumor therapies: complex links
Abstract
Myeloid cells infiltrating the tumor microenvironment, especially tumor-associated macrophages (TAMs), are essential providers of cancer-related inflammation, a condition known to accelerate tumor progression and limit the response to anti-tumor therapies. As a matter of fact, TAMs may have a dual role while interfering with cancer treatments, as they can either promote or impair their functionality. Here we review the connection between macrophages and anticancer therapies; moreover, we provide an overview of the different strategies to target or re-program TAMs for therapeutic purposes.
Keywords: Anti-tumor therapies; Cancer-related inflammation; Macrophage targeting; Nanoparticles; Tumor-associated macrophages.
Figures

Similar articles
-
Understanding the Origin and Diversity of Macrophages to Tailor Their Targeting in Solid Cancers.Front Immunol. 2019 Sep 25;10:2215. doi: 10.3389/fimmu.2019.02215. eCollection 2019. Front Immunol. 2019. PMID: 31611871 Free PMC article. Review.
-
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses.Cells. 2019 Dec 23;9(1):46. doi: 10.3390/cells9010046. Cells. 2019. PMID: 31878087 Free PMC article. Review.
-
Tumor-associated macrophages: a short compendium.Cell Mol Life Sci. 2019 Apr;76(8):1447-1458. doi: 10.1007/s00018-018-2997-3. Epub 2019 Feb 12. Cell Mol Life Sci. 2019. PMID: 30747250 Free PMC article. Review.
-
Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer.Adv Exp Med Biol. 2017;1026:331-370. doi: 10.1007/978-981-10-6020-5_16. Adv Exp Med Biol. 2017. PMID: 29282692 Review.
-
The interaction of anticancer therapies with tumor-associated macrophages.J Exp Med. 2015 Apr 6;212(4):435-45. doi: 10.1084/jem.20150295. Epub 2015 Mar 9. J Exp Med. 2015. PMID: 25753580 Free PMC article. Review.
Cited by
-
Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma.Mol Ther Oncolytics. 2022 Mar 16;25:98-120. doi: 10.1016/j.omto.2022.03.002. eCollection 2022 Jun 16. Mol Ther Oncolytics. 2022. PMID: 35506150 Free PMC article. Review.
-
Anti-cancer targets and molecular mechanisms of formononetin in treating osteosarcoma based on network pharmacology.Aging (Albany NY). 2023 Oct 20;15(20):11489-11507. doi: 10.18632/aging.205139. Epub 2023 Oct 20. Aging (Albany NY). 2023. PMID: 37870753 Free PMC article.
-
Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy.Eur J Immunol. 2021 Nov;51(11):2677-2686. doi: 10.1002/eji.202149379. Epub 2021 Oct 8. Eur J Immunol. 2021. PMID: 34570376 Free PMC article.
-
Exosomal long non-coding RNAs in cancer: Interplay, modulation, and therapeutic avenues.Noncoding RNA Res. 2024 Apr 4;9(3):887-900. doi: 10.1016/j.ncrna.2024.03.014. eCollection 2024 Sep. Noncoding RNA Res. 2024. PMID: 38616862 Free PMC article. Review.
-
Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma.Front Oncol. 2022 Nov 3;12:914342. doi: 10.3389/fonc.2022.914342. eCollection 2022. Front Oncol. 2022. PMID: 36408147 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials